China Tightens Scrutiny Of Drug Ads

25 September 1997

The Chinese government is to increase its scrutiny of television andnewspaper advertisements to ensure the promotion of medicines and medical equipment and services is authentic, scientific and legal, reports Chinese Medical News.

The State Administration of Industry and Commerce, the state agency in charge of the advertising sector, has issued a circular calling for the industry, commerce bureaux and health departments to improve their examination and supervision of such advertisements.

The SAIC says that in April, 49% of medical ads published in China's main newspapers, or 1,799 out of a total 3,649 promotions, failed to follow the stipulations of China's advertising laws. In future, says the circular, companies violating the laws will be temporarily banned from advertising their products and subject to severe penalties.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight